trending Market Intelligence /marketintelligence/en/news-insights/trending/pkxvtjfj56n5fnoli_upfa2 content esgSubNav
In This List

Pieris Pharmaceuticals adds board member

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Pieris Pharmaceuticals adds board member

Boston-based Pieris Pharmaceuticals Inc. added Peter Kiener as a member of its board.

Kiener served as chief scientific officer at Sucampo AG until its acquisition by Mallinckrodt earlier this year. He has also served as the chief scientific officer at Ambrx Inc. and as the president and co-founder of Zyngenia Inc., which develops monoclonal antibodies to treat oncology and inflammatory diseases.

He has also held research and development positions at MedImmune LLC and Bristol-Myers Squibb Co.

Pieris has several preclinical and clinical-stage drugs in the pipeline based on its Anticalin protein technology. The company's focus is on immuno-oncology and respiratory diseases, for which it has partnered with Servier International and AstraZeneca PLC respectively.